Securities Suit Filed Against Ardelyx Over Alleged Fraud
Investors have filed securities class actions against Ardelyx, alleging the company misrepresented the outlook for IBSRELA and XPHOZAH while payer restrictions hindered access and prescription growth. The suits follow Ardelyx’s lowered IBSRELA revenue forecast and withdrawal of long-term XPHOZAH guidance, after which its shares fell sharply; investors have until November 16, 2026, to seek lead-plaintiff status.
Finance · 6 sources · 3hRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About tenapanor
Tenapanor, sold under the brand name Ibsrela among others, is a medication used for the treatment of adults with a disease of the gut called irritable bowel syndrome with constipation commonly referred to as IBS-C. It is used in form of tenapanor hydrochloride. It is also used in the treatment of hyperphosphatemia associated with chronic kidney disease. Tenapanor is a sodium hydrogen exchanger 3 (NHE3) inhibitor.
Everything about tenapanor →